Eisai Listed for 17th Consecutive Year in FTSE4GOOD Index Series

Product name:Eisai Listed for 17th

2018/07/05 update

Industry:BioTech

An Index for Socially Responsible Investment

TOKYO, Jul 4, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 17th consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series is a global index series for socially responsible investment.

The FTSE4Good Index Series is designed to help investors integrate environmental, social and governance (ESG) factors into their investment decisions. Of the 14 themes evaluated, Eisai received particularly high scores in "Customer Responsibility", "Corporate Governance", "Anti-Corruption", "Water Use", "Climate Change" and "Labor Standards", among others. As of June 2018, a total of 925 companies from around the world have been selected for the FTSE4Good Developed Index, including 152 companies from Japan.

Along with being listed in the FTSE4Good Index Series, Eisai is also listed in the Dow Jones Sustainability Asia Pacific Index, another representative index for socially responsible investment, as well as the MSCI Japan Empowering Women Index (WIN), the FTSE Blossom Japan Index, and the MSCI Japan ESG Select Leaders Index, which are the three ESG investment indices for Japanese stocks adopted by the Government Pension Investment Fund (GPIF).

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this corporate philosophy.

About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Copyright 2018 JCN Newswire. All rights reserved. www.jcnnewswire.com

Spec

  • Product name

    Eisai Listed for 17th

Review

  • Document Rrequest
  • Campaign
  • Monitor